Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Cancer Stage II Clear all
Completed Not applicable Interventional Results available

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

NCT01797159
View directory record Official record
Conditions
Small-cell Lung Cancer, SCLC, Small Cell Lung Cancer Limited Stage
Interventions
Hippocampal-sparing Prophylactic Cranial Irradiation
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

NCT00741988
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ixabepilone, Carboplatin, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
13
States / cities
Fort Myers, Florida • Gainesville, Florida • Terre Haute, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional Results available

Phase II Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Tumors of the Lung

NCT00832780
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Solid Tumors
Interventions
Stereotactic Body Radiation
Radiation
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

NCT06769126
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
148
States / cities
Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Trial of Poor Performance Status Patients (ToPPS)

NCT00892710
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Bevacizumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Withdrawn Phase 2 Interventional

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

NCT04470674
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation
Interventions
Durvalumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Shirish M Gadgeel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735
View directory record Official record
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer

NCT00906282
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pemetrexed, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
12
States / cities
Fort Myers, Florida • Augusta, Georgia • Gainesville, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

NCT00165503
View directory record Official record
Conditions
Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions
Cisplatin, Sodium Thiosulfate, ALIMTA
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer

NCT01459497
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Radiation Therapy, Conventional radiation
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
7
States / cities
Austin, Texas • Dallas, Texas • Houston, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00182689
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Interventions
sorafenib tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT01557959
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, pegfilgrastim, erlotinib hydrochloride, laboratory biomarker analysis, polymorphism analysis, pharmacogenomic studies, genetic linkage analysis, docetaxel
Drug · Biological · Other + 1 more
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)

NCT03840915
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cisplatin, Carboplatin, Pemetrexed, Nab-paclitaxel, Gemcitabine, Docetaxel, M7824, Bintrafusp alfa, Paclitaxel
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • San Marcos, California • Port Saint Lucie, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 1Phase 2 Interventional

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

NCT01573338
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Roniciclib (BAY1000394), Etoposide, Cisplatin, Carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
St Louis, Missouri • Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Not applicable Interventional

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers

NCT02243748
View directory record Official record
Conditions
Caregiver, Psychological Impact of Cancer and Its Treatment, Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Palliative Therapy, quality-of-life assessment, questionnaire administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Ontario, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

NCT03425006
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Itacitinib, Pembrolizumab
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer

NCT01493843
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
pictilisib, Placebo, bevacizumab, carboplatin, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Rogers, Arkansas • Encinitas, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

NCT06750185
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5, BNT317 DL6, BNT317 selected DLA, BNT317 selected DLB, SoC chemotherapy 1, SoC chemotherapy 2
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Louisville, Kentucky • Grand Rapids, Michigan • Huntersville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer

NCT00022711
View directory record Official record
Conditions
Lung Cancer
Interventions
temozolomide
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
17
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02965378
View directory record Official record
Conditions
FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Amplification, FGFR3 Gene Mutation, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions
Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
25 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1083
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 672 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 17, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

NCT06262321
View directory record Official record
Conditions
Stage 4 NSCLC, Radiotherapy
Interventions
Prophylactic Palliative Radiotherapy
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 17, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional

Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00040768
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
bortezomib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 17, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

NCT01443078
View directory record Official record
Conditions
Lung Cancer
Interventions
pemetrexed, cisplatin, Carboplatin, Gemcitabine Hydrochloride, Vinorelbine Tartrate, Docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 17, 2026, 5:14 AM EDT